Cure Today7h
Imfinzi Improves Survival Outcomes in Subgroups of Patients with LS-SCLC
Among patients with limited-stage small cell lung cancer, the benefits of consolidation Imfinzi were seen across a number of ...
FiercePharma9d
ESMO: AstraZeneca's Imfinzi extends life in bladder cancer type. Will FDA push back on its perioperative trial design?
AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...
GlobalData on MSN7d
AstraZeneca’s Imfinzi and Imjudo found to extend survival in liver cancer trial
Imfinzi is a human monoclonal antibody that targets the PD-L1 protein, whereas Imjudo focuses on the CTLA-4 protein.
AstraZeneca Pharma shares jump 12% to 52-week high on CDSCO permission
The company has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution ...
Astra’s Blockbuster Drug Scores Major Win in Bladder Cancer
AstraZeneca Plc’s Imfinzi extended the lives of patients with bladder cancer, potentially opening up a new market for the ...
FiercePharma5h
AstraZeneca shows ‘What Science Can Do’ for patients’ lives in new video series
The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics. Each of their ...
moneycontrol.com19h
Stock Radar: ONGC, Reliance, PNB, AstraZeneca, GR Infra, BGR Energy, Arkade Developers, Coal India in focus on Tuesday
The company has received approval to import, sell, and distribute Durvalumab Solution for infusion (Imfinzi) from the ...
AIM Reports Positive Preliminary Data From Phase 1b/2 Study Of Ampligen, Imfinzi As Combination
AIM ImmunoTech (AIM) reported positive preliminary data from the Phase 1b/2 study evaluating the combination of Ampligen and ...